The first of these patents covers the company’s HDL Selective Delipidation technology. HDL Selective Delipidation modifies naturally occurring HDL resulting in the creation of a substantially more effective scavenger form of HDL. This ‘energized’ HDL has been shown to dramatically increase reverse cholesterol transport, the body’s process for removing cholesterol from plaque in the cardiovascular system.
The second patent covers the ability of the company’s delipidation process to modify cancer cells and create a cancer cell antigen – demonstrating the potential of this novel process to develop a range of cancer vaccines.
Lewis Meyer, president and CEO of Lipid Sciences, said: “We have established a strong intellectual property position supporting a wide range of applications of our targeted lipid removal technology. Patent protection for HDL Selective Delipidation creates significant, potential value for this breakthrough cardiovascular disease therapy.”